ORIC Pharmaceuticals, Inc. Shareholders Are Encouraged to
Johnson Fistel, PLLP is investigating potential claims on behalf of investors of ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) following a significant stock price decline on April 1, 2026. The investigation stems from ORIC's March 31, 2026, disclosure of additional clinical data and program updates, after which the stock fell by approximately 26%. The law firm is examining whether ORIC's executive officers complied with federal securities laws and is encouraging affected shareholders to join their investigation.
ORIC Pharmaceuticals, Inc. Shareholders Are Encouraged to
Johnson Fistel, PLLP is investigating potential claims against ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) on behalf of investors who suffered losses. This investigation follows a 26% stock price decline after ORIC reported clinical data on March 31, 2026, which included information on tolerability, comparable efficacy, and response rates that impacted investor confidence. The law firm aims to determine if ORIC complied with federal securities laws and to help investors recover their losses.
A Look At ORIC Pharmaceuticals (ORIC) Valuation After Advancing Rinzimetostat To A Phase 3 Prostate Cancer Trial
ORIC Pharmaceuticals (ORIC) is advancing its prostate cancer drug rinzimetostat into a Phase 3 trial, following detailed Phase 1b data. Despite recent stock volatility, analysts project a significant upside for the stock, trading at an implied discount compared to the average target price of $21.00. However, the company's valuation faces challenges due to its lack of current revenue, ongoing losses, and the inherent risks of clinical-stage biotech.
ORIC Pharmaceuticals Reports Inducement Grants
ORIC Pharmaceuticals, a clinical-stage oncology company, has granted 80,000 non-qualified stock options and 15,000 restricted stock units to a new non-executive employee who joined in March 2026. These inducement grants aim to attract and retain top talent, aligning new hires' interests with the company's advancement of its oncology pipeline. The grants vest over one to three years, with an exercise price matching the closing stock price on the April 1, 2026 grant date.
ORIC Pharmaceuticals (ORIC) Is Down 28.2% After Selecting 400 mg Rinzimetostat Dose for Phase 3
ORIC Pharmaceuticals experienced a share price drop after selecting a 400 mg rinzimetostat dose for its Phase 3 Himalayas-1 registrational trial for metastatic castration-resistant prostate cancer. The decision was based on favorable tolerability and an 84% 5-month radiographic progression-free survival rate, aligning with the FDA’s Project Optimus. Investors are now closely watching the single registrational trial, as the company faces ongoing losses and relies heavily on this clinical progress.
ORIC Pharmaceuticals Reports Inducement Grants
ORIC Pharmaceuticals, a clinical-stage oncology company, announced inducement grants for a new non-executive employee on April 1, 2026. The grants, totaling 80,000 non-qualified stock options and 15,000 restricted stock units, aim to attract and retain top talent in the competitive biotech industry. These equity incentives align the employee's interests with those of shareholders and are part of the company's 2022 Inducement Equity Incentive Plan.
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
ORIC Pharmaceuticals announced inducement grants to a new non-executive employee on April 1, 2026. The grants included 80,000 non-qualified stock options and 15,000 restricted stock units, approved by ORIC's Compensation Committee in accordance with Nasdaq Rule 5635(c)(4). These grants are subject to vesting schedules and are intended to be a material inducement to employment.
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
ORIC Pharmaceuticals announced inducement grants on April 1, 2026, comprising 80,000 non-qualified stock options and 15,000 restricted stock units to a new non-executive employee. These grants, approved by ORIC's Compensation Committee as a material inducement for employment under Nasdaq Rule 5635(c)(4), will vest over several years subject to continued employment. ORIC Pharmaceuticals is a clinical-stage oncology company developing treatments to overcome therapeutic resistance in cancer.
What's Behind The Drop In Oric Pharmaceuticals Stock Today?
Shares of Oric Pharmaceuticals (NASDAQ: ORIC) are declining after the company provided an update from its Phase 1b trial for rinzimetostat. Despite positive data showing an 84% progression-free survival rate in prostate cancer patients and plans for a Phase 3 trial, the stock is experiencing a de-risking event. The drop is specific to ORIC and not sector-driven, pushing the stock toward key support levels.
HC Wainwright Reaffirms Buy Rating for Oric Pharmaceuticals (NASDAQ:ORIC)
HC Wainwright has reiterated a "Buy" rating for Oric Pharmaceuticals (NASDAQ:ORIC), setting a $25 price target, despite the stock falling significantly due to safety concerns from earlier trial data. The company has selected a recommended Phase 3 dose for its prostate cancer candidate, rinzimetostat, with trials expected to begin in the first half of 2026. This comes as CFO Dominic Piscitelli reduced his stake in the company through a share sale, yet institutional investors maintain a substantial holding.
ORIC Pharmaceuticals’ Global Ambitions amid Tumultuous Share Movements
Oric Pharmaceuticals Inc. (NASDAQ: ORIC) recently saw its stock rise by 12.91% following promising FDA designations and trial results, despite market volatility driven by concerns over early treatment discontinuations. Analysts suggest the stock dip is excessive, recommending investors buy the dip, especially given the company's planned global Phase 3 trials for its prostate cancer treatment. While financial reports show strategic but risky operations with profitability challenges, ORIC's efficacy comparable to major competitors positions it for potential long-term value.
Oric Pharmaceuticals (ORIC) Receives a Buy from Evercore ISI
Evercore ISI analyst Cory Kasimov maintained a Buy rating on Oric Pharmaceuticals (ORIC) with a $25.00 price target, based on his 16.0% average return and 54.79% success rate in the Healthcare sector. Piper Sandler also issued a Buy rating for the company, despite a recent Hold reiterated by TipRanks – xAI. The company reported a reduced GAAP net loss of $30.51 million for the quarter ending December 31, compared to $36.31 million last year.
ORIC Pharma drops after early-stage trial data for prostate cancer therapy
ORIC Pharmaceuticals' stock dropped significantly after announcing early-stage trial results for its prostate cancer therapy, ORIC-114. Despite the company stating the data supported further development, investors reacted negatively to the findings, which included an objective response rate of 4% and a stable disease rate of 57% in a heavily pre-treated patient group. The trial is now advancing to an expansion dose cohort.
ORIC plans 600-patient prostate cancer Phase 3 after early durability data
ORIC Pharmaceuticals has selected rinzimetostat 400 mg once daily as the recommended Phase 3 dose for its Himalayas-1 global registrational trial in metastatic castration-resistant prostate cancer (mCRPC), expected to start in the first half of 2026. Early Phase 1b data showed strong durability with landmark rPFS rates of 84% at 5 months and a favorable safety profile compared to competitor regimens. The trial will enroll approximately 600 patients, aiming for a potential "best-in-disease" therapy in a market with significant unmet needs.
What's Behind The Drop In Oric Pharmaceuticals Stock Today?
Shares of Oric Pharmaceuticals (NASDAQ: ORIC) significantly dropped despite positive updated Phase 1b data for its prostate cancer drug rinzimetostat. The company reported an 84% radiographic progression-free survival rate and plans to initiate a Phase 3 trial, but the stock experienced stock-specific de-risking. The decline pushed ORIC below key moving averages, though it remains closer to its 52-week highs and shows mixed momentum indicators.
Oric Pharmaceuticals (NASDAQ:ORIC) Given New $17.00 Price Target at Wedbush
Wedbush has lowered its price target for Oric Pharmaceuticals (NASDAQ:ORIC) from $20.00 to $17.00 while maintaining an "outperform" rating, indicating a potential upside of approximately 34%. Despite this adjustment, the stock maintains a "Moderate Buy" consensus rating among analysts with an average price target of $19.90. Insider transactions show the company's CFO sold a significant portion of shares, though institutional investors hold a substantial 95.05% of the stock.
Oric Advances Rinzimetostat Toward First Prostate Cancer Phase 3
Oric Pharmaceuticals (ORIC) has chosen a 400 mg once-daily dose of rinzimetostat combined with darolutamide as its provisional Phase 3 regimen for prostate cancer, based on positive efficacy and safety profiles from its Phase 1b trial. The company plans to start its first Phase 3 trial in post-abiraterone metastatic castration-resistant prostate cancer in the first half of 2026, aiming to address a significant unmet need with an oral, well-tolerated therapy. Spark, TipRanks’ AI Analyst, rates ORIC as Neutral due to strong financials but lack of revenue and ongoing losses.
Rinzimetostat Phase 3 dose and cash runway update from ORIC (NASDAQ: ORIC)
ORIC Pharmaceuticals announced it is advancing rinzimetostat (ORIC-944) to Phase 3 at a 400 mg once-daily dose in combination with darolutamide for metastatic castration-resistant prostate cancer, based on favorable efficacy and a differentiated safety profile from Phase 1b optimization data. The company reported strong PSA responses and a good tolerability profile at this dose, with fewer adverse events and dose modifications compared to higher doses or competitor regimens. ORIC also updated its financial position, showing approximately $412 million in cash and investments, providing a cash runway into the second half of 2028, sufficient to execute planned registrational trials for rinzimetostat and another late-stage candidate, enozertinib.
ORIC Falls After Hours On Safety Concerns Around Prostate Cancer Candidate At Higher Doses
ORIC Pharmaceuticals (ORIC) stock fell 25% after hours due to safety concerns regarding its prostate cancer drug, rinzimetostat, at higher doses. An early-stage trial showed that a 600 mg dose had a higher rate of adverse events compared to the 400 mg dose. The company plans to proceed with a global late-stage trial using the 400 mg once-daily dose, citing a cleaner safety profile and promising early efficacy data, despite some grade 3 treatment-related adverse events.
Oric Pharmaceuticals Unveils Rinzimetostat Phase Ib Data, Sets Stage for Phase III Himalayas-1 Trial
Oric Pharmaceuticals announced new Phase Ib data for its PRC2 inhibitor rinzimetostat, identifying 400 mg once daily as the optimal dose for metastatic castration-resistant prostate cancer (mCRPC) when combined with darolutamide. This dose showed comparable efficacy to a higher dose but with fewer toxicities. The company is now preparing to launch the registrational Phase III Himalayas-1 trial in Q2, with top-line data expected in late 2027 or early 2028, targeting a significant market in post-abiraterone mCRPC.
The Technical Signals Behind (ORIC) That Institutions Follow
This article provides a technical analysis of Oric Pharmaceuticals Inc. (NASDAQ: ORIC), focusing on institutional trading signals and strategies. It highlights a near-term strong sentiment transitioning to mid-term neutrality and then a long-term positive bias, noting a current breakdown with expected lower levels. The report details specific position, momentum, and risk-hedging trading strategies, along with multi-timeframe signal analysis for support and resistance levels.
ORIC® Pharmaceuticals Reports Selection of Rinzimetostat
ORIC Pharmaceuticals announced the selection of rinzimetostat (ORIC-944) 400 mg once daily as the Recommended Phase 3 Dose (RP3D) for the Himalayas-1 global Phase 3 registrational trial. The drug, in combination with darolutamide, demonstrated promising efficacy and a favorable safety profile for patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with abiraterone. This decision is supported by dose optimization data suggesting a potential best-in-disease profile, with trial initiation expected in the first half of 2026.
A Look At ORIC Pharmaceuticals (ORIC) Valuation As Rinzimetostat Phase 1b Data Update Approaches
ORIC Pharmaceuticals (ORIC) is garnering attention due to its upcoming Phase 1b data update for rinzimetostat in prostate cancer, following significant share price growth over the past year. Despite trading at a discount to analyst targets, the company is still in a loss-making clinical stage, with a discounted cash flow (DCF) model suggesting it is undervalued at $43.66 per share compared to its current price of $12.06. Investors are cautioned that this valuation relies heavily on future trial success and commercialization, while the price-to-book ratio indicates a more cautious outlook than the DCF model.
ORIC Pharmaceuticals to report prostate cancer trial data Tuesday
ORIC Pharmaceuticals (NASDAQ:ORIC) is set to report combination dose optimization data from its Phase 1b trial of rinzimetostat in patients with metastatic castration-resistant prostate cancer on Tuesday, March 31, 2026. This clinical stage oncology company will host a conference call and webcast to discuss the data. The announcement comes amidst market challenges for EZH2 inhibitors, though analysts maintain a generally positive outlook on ORIC Pharmaceuticals' stock.
ORIC® Pharmaceuticals to Report Combination Dose Optimization Data From Phase 1b Trial of Rinzimetostat in Patients with mCRPC
ORIC Pharmaceuticals announced it will report combination dose optimization data from its Phase 1b trial of rinzimetostat (ORIC-944) for metastatic castration-resistant prostate cancer (mCRPC). The company will host a conference call and webcast on Tuesday, March 31, 2026, at 4:30 pm ET to discuss the findings. ORIC Pharmaceuticals is a clinical-stage oncology company focused on developing treatments to overcome therapeutic resistance in cancer.
ORIC® Pharmaceuticals to Report Combination Dose Optimization Data From Phase 1b Trial of Rinzimetostat in Patients with mCRPC
ORIC Pharmaceuticals announced it will report combination dose optimization data from the Phase 1b trial of rinzimetostat (ORIC-944) in patients with metastatic castration-resistant prostate cancer (mCRPC). The company will host a conference call and webcast on Tuesday, March 31, 2026, at 4:30 pm ET to discuss the findings. Rinzimetostat is an allosteric inhibitor of PRC2 being developed for prostate cancer.
ORIC® Pharmaceuticals to Report Combination Dose Optimization Data From Phase 1b Trial of Rinzimetostat in Patients with mCRPC
ORIC Pharmaceuticals will report combination dose optimization data from its Phase 1b trial of rinzimetostat (ORIC-944) for metastatic castration-resistant prostate cancer (mCRPC) on Tuesday, March 31, 2026. The company will host a conference call and webcast to discuss the findings from this clinical stage product candidate. Rinzimetostat is an allosteric inhibitor of PRC2, developed to overcome therapeutic resistance in cancer.
ORIC Pharmaceuticals to report prostate cancer trial data Tuesday By Investing.com
ORIC Pharmaceuticals (NASDAQ:ORIC) is set to release combination dose optimization data from its Phase 1b trial of rinzimetostat for metastatic castration-resistant prostate cancer on Tuesday, March 31, 2026. The clinical-stage oncology company will host a conference call and webcast to discuss the findings for its drug, also known as ORIC-944. Despite recent challenges in the EZH2 inhibitor space, ORIC's stock has seen strong returns, and several firms maintain positive ratings on the company.
ORIC Pharmaceuticals to Report Combination Dose Optimization Data From Phase 1b Trial of Rinzimetostat in Patients with mCRPC
ORIC Pharmaceuticals announced that it will report combination dose optimization data from the Phase 1b trial of rinzimetostat (ORIC-944) in patients with metastatic castration resistant prostate cancer (mCRPC). The company will host a conference call and webcast on Tuesday, March 31, 2026, at 4:30 pm ET to discuss these findings. ORIC Pharmaceuticals is a clinical-stage oncology company focused on developing treatments to overcome therapeutic resistance in cancer.
JPMorgan Chase & Co. Sells 106,920 Shares of Oric Pharmaceuticals, Inc. $ORIC
JPMorgan Chase & Co. has reduced its stake in Oric Pharmaceuticals, selling 106,920 shares, now holding 1.26% of the company valued at $14.74 million. Other institutional investors like AQR Capital Management and Goldman Sachs Group Inc. increased their positions. Despite insider selling by Oric's CFO, analysts maintain a "Moderate Buy" rating with an average target price of $20.20 for the stock.
ORIC® Pharmaceuticals to Report Combination Dose Optimization Data From Phase 1b Trial of Rinzimetostat in Patients with mCRPC
ORIC Pharmaceuticals will report combination dose optimization data from its Phase 1b trial of rinzimetostat in patients with metastatic castration-resistant prostate cancer (mCRPC). The company is hosting a conference call and webcast on Tuesday, March 31, 2026, at 4:30 pm ET to discuss these findings. Rinzimetostat is an allosteric inhibitor of PRC2 via the EED subunit, and ORIC Pharmaceuticals is a clinical-stage oncology company focused on overcoming therapeutic resistance.
Oric Pharmaceuticals (NASDAQ:ORIC) Trading Up 7% - Here's What Happened
Oric Pharmaceuticals (NASDAQ:ORIC) shares gained 7% on Thursday. Analysts have a "Moderate Buy" consensus rating with an average price target of $20.20, although the CFO recently sold a significant portion of his stake. The company surpassed EPS expectations in its last earnings report.
ORIC® Pharmaceuticals Announces Preclinical Rinzimetostat (ORIC-944) Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting
ORIC Pharmaceuticals announced that multiple abstracts highlighting the potential of rinzimetostat (ORIC-944) for treating prostate cancer have been accepted for presentation at the 2026 AACR Annual Meeting. Preclinical studies indicate rinzimetostat, an allosteric PRC2 inhibitor, demonstrates superior efficacy in acquired resistance contexts compared to other EZH2 and EZH1/2 inhibitors. The data suggest rinzimetostat can re-sensitize ARPI-resistant tumors and block prostate tumor adaptation, with a global Phase 1b trial ongoing.
Precision Trading with Oric Pharmaceuticals Inc. (ORIC) Risk Zones
Oric Pharmaceuticals Inc. (ORIC) shows weak near and mid-term sentiment despite a positive long-term outlook. The article outlines three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss zones. It also provides multi-timeframe signal analysis indicating strong long-term support and resistance levels.
ORIC® Pharmaceuticals Announces Preclinical Rinzimetostat
ORIC Pharmaceuticals announced that multiple abstracts highlighting the potential of rinzimetostat (ORIC-944) for treating prostate cancer will be presented at the 2026 AACR Annual Meeting. Preclinical studies show rinzimetostat, an allosteric EED inhibitor, maintains potency against PRC2 complexes with EZH1 or EZH2 and is effective in contexts of resistance to EZH2 and EZH1/2 inhibitors. The findings suggest rinzimetostat could re-sensitize ARPI-resistant tumors and block prostate tumor adaptation, with a global phase 1b trial currently underway.
Experimental prostate cancer drug targets treatment resistance in lab tests
ORIC Pharmaceuticals announced that preclinical data for its experimental prostate cancer drug, rinzimetostat (ORIC-944), will be presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The data suggest that rinzimetostat, an allosteric PRC2 inhibitor, effectively targets treatment resistance mechanisms and improves the response to androgen receptor inhibitors in prostate cancer models. This news led to a moderate positive market reaction for ORIC stock, with a 3.40% gain.
A Look At ORIC Pharmaceuticals (ORIC) Valuation After Competitor Tazverik Withdrawal And Analyst Support
ORIC Pharmaceuticals (ORIC) experienced stock pressure after a competitor's cancer drug withdrawal, Tazverik, though ORIC asserts its own candidate shows no similar malignancy concerns. Despite short-term volatility, ORIC's shares have shown strong year-to-date and 1-year returns, prompting questions about its current valuation. While its Price-to-Book ratio suggests it's expensive compared to the broader biotech industry, a Discounted Cash Flow model indicates significant undervaluation, with an estimated future cash flow value of $43.76 per share against its current $11.90.
A Look At ORIC Pharmaceuticals (ORIC) Valuation After Competitor Tazverik Withdrawal And Analyst Support
ORIC Pharmaceuticals (ORIC) experienced stock pressure following Ipsen's withdrawal of the cancer drug Tazverik, despite ORIC's own prostate cancer candidate, rinzimetostat, showing no similar safety concerns in preclinical tests. Despite its Price-to-Book ratio of 3.1x appearing rich compared to the broader US biotech industry, a Discounted Cash Flow (DCF) model suggests ORIC is undervalued, with a fair value of $43.76 per share against its current $11.90. This discrepancy raises questions about whether the market is overly cautious, urging investors to consider both potential upside and risks.
Oric Pharmaceuticals, Inc. $ORIC Position Reduced by ArrowMark Colorado Holdings LLC
ArrowMark Colorado Holdings LLC recently reduced its stake in Oric Pharmaceuticals (NASDAQ:ORIC) by 14.2% in the third quarter, selling 180,957 shares and retaining over 1 million shares valued at approximately $13.17 million. This move comes as company insiders have also been net sellers, with CEO Jacob Chacko and another insider selling shares totaling over $1.20 million in the past three months. Despite insider selling, analysts maintain a "Moderate Buy" consensus and a price target of $20.20 for ORIC, which is currently trading around $11.90.
ORIC Pharmaceuticals (ORIC) Is Down 15.1% After Peer Drug Withdrawal Triggers Safety Scrutiny - What's Changed
Shares of ORIC Pharmaceuticals (ORIC) fell by 15.1% after Ipsen voluntarily withdrew its EZH2 inhibitor Tazverik due to safety concerns, prompting scrutiny of similar oncology approaches. ORIC responded by emphasizing that its PRC2 inhibitor, rinzimetostat, has shown no malignancies in preclinical studies and highlighted continued analyst confidence. The article discusses how these safety concerns and ORIC's differentiation efforts shape the company's investment narrative, noting potential downside despite some community members seeing fair value above the current price.
Integral Health Asset Management LLC Cuts Stock Position in Oric Pharmaceuticals, Inc. $ORIC
Integral Health Asset Management LLC significantly reduced its stake in Oric Pharmaceuticals ($ORIC) by 28.0% in the third quarter of 2026, selling 350,000 shares. Despite this reduction, other institutional investors increased their holdings, and analysts maintain a "Moderate Buy" rating with a target price of $20.20 for the stock. Insider selling, including by the CEO and another executive, totaled over $1.19 million in the last quarter.
Oric Pharmaceuticals' (ORIC) Buy Rating Reaffirmed at HC Wainwright
HC Wainwright has reaffirmed its “Buy” rating for Oric Pharmaceuticals (ORIC) with a $25.00 price target, suggesting a 111.5% upside. Despite this, insiders, including CEO Jacob Chacko, have recently sold over 106,000 shares. The company has a consensus "Moderate Buy" rating from analysts with an average target price of $20.20, and institutional investors own a significant 95.05% of the stock.
ORIC Pharmaceuticals (ORIC) Is Down 15.1% After Peer Drug Withdrawal Triggers Safety Scrutiny - What's Changed
ORIC Pharmaceuticals (ORIC) shares dropped 15.1% after Ipsen voluntarily withdrew its EZH2 inhibitor, Tazverik, due to safety concerns, prompting increased scrutiny on similar oncology drugs. ORIC has stated that its PRC2 inhibitor, rinzimetostat, has shown no malignancies in preclinical studies, and analysts maintain confidence in its pipeline. The article discusses how this event impacts ORIC's investment narrative, particularly concerning its ongoing clinical programs and financial needs, while also noting that some community members still see ORIC's fair value significantly above its current price despite the new safety concerns.
ORIC Pharmaceuticals: Differentiated PRC2 Inhibitor Rinzimetostat Mitigates Sector Safety Overhang and Supports Buy Rating
JonesTrading analyst Soumit Roy maintained a Buy rating on ORIC Pharmaceuticals with a $25.00 price target. Roy's decision is based on ORIC's lead drug, rinzimetostat, a differentiated allosteric PRC2 inhibitor, which avoids the safety concerns observed with a peer drug, Ipsen’s EZH2 inhibitor Tazverik. The analyst highlights rinzimetostat's distinct mechanism of action and strong early Phase 1b safety data, suggesting Tazverik's setback does not negatively impact ORIC.
March 2026 Cantor Fitzgerald Maintains Overweight on ORIC (ORIC)
Cantor Fitzgerald maintained an Overweight rating for ORIC Pharmaceuticals, Inc. (ORIC) on March 9, 2026, viewing a recent stock drop as an "over-reaction." Conversely, Wolfe Research maintained a Negative rating on the same day, citing "mixed" newsflow following a 12% decline. Despite these differing views, neither firm issued a new price target, leaving ORIC's market sentiment split and its future performance driven by fundamentals and upcoming data.
Oric Pharmaceuticals stock tumbles on Tazverik withdrawal
Oric Pharmaceuticals Inc. (NASDAQ:ORIC) saw its stock fall 18.5% after Ipsen announced the withdrawal of Tazverik (tazemetostat) from all markets due to observed secondary hematologic malignancies in a Phase 3 trial. Analysts view this withdrawal as a negative for the broader EZH2 inhibitor space, raising concerns about potential safety signals impacting other similar drugs. The future performance of Oric shares is expected to significantly depend on outcomes from the upcoming Mevpro-1 readout.
ORIC Pharmaceuticals Shares Drop Following Ipsen's Drug Withdrawal
Oric Pharmaceuticals (ORIC) experienced a 12% stock price decline after Ipsen withdrew its drug Tazverik due to safety concerns highlighted by new Phase Ib/III SYMPHONY-1 trial findings. Despite being a clinical-stage company with no revenue, ORIC maintains strong financial health with high liquidity and low debt. However, insider selling and negative profitability metrics indicate potential short-term challenges for the biotechnology firm.
After the Golden Cross, the technical perspective for Oric Pharmaceuticals, Inc. (ORIC) appears promising
Oric Pharmaceuticals (ORIC) is showing promising technical indicators following a "golden cross," where its 50-day simple moving average surpassed its 200-day simple moving average. This bullish signal, combined with a 31.6% surge in the last month and improved Zacks earnings projections, suggests potential for continued growth. Investors are advised to watch ORIC closely due to these positive technical and fundamental developments.
After Golden Cross, Oric Pharmaceuticals, Inc. (ORIC)'s Technical Outlook is Bright
Oric Pharmaceuticals, Inc. (ORIC) is showing a strong technical outlook after its 50-day simple moving average crossed above its 200-day simple moving average, forming a "golden cross." This bullish indicator, combined with a #3 (Hold) Zacks Rank and positive earnings estimates, suggests potential for further gains. Investors are advised to monitor ORIC as it has gained 31.6% in the last four weeks and has a favorable earnings outlook.
Oric Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Oric Pharmaceuticals (ORIC) has reported inducement grants made under Nasdaq Listing Rule 5635(C)(4). This brief article from Reuters signals a compliance-related disclosure for the pharmaceutical company.
